PriceTargets.com logo

Century Therapeutics - IPSC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 458.82%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$3.40 As of 03/30/2023 01:00 AM ET
▼ -0.13 (-3.68%)

This chart shows the closing price for IPSC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Century Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPSC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPSC

Analyst Price Target is $19.00
▲ +458.82% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Century Therapeutics in the last 3 months. The average price target is $19.00, with a high forecast of $28.00 and a low forecast of $14.00. The average price target represents a 458.82% upside from the last price of $3.40.

This chart shows the closing price for IPSC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Century Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2023Chardan CapitalReiterated RatingBuy$19.00Low
3/17/2023Bank of AmericaLower Target$23.00 ➝ $20.00Low
3/17/2023HC WainwrightLower TargetBuy$19.00 ➝ $17.00Low
3/16/2023EF Hutton Acquisition Co. IReiterated RatingBuy$16.00Low
2/9/2023HC WainwrightReiterated RatingBuy$19.00Low
1/6/2023Piper SandlerLower TargetOverweight$24.00 ➝ $14.00Low
1/6/2023SVB LeerinkLower TargetOutperform$20.00 ➝ $14.00Low
1/6/2023HC WainwrightLower TargetBuy$25.00 ➝ $19.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$18.00Low
12/27/2022Chardan CapitalInitiated CoverageBuy$19.00Low
11/14/2022HC WainwrightLower TargetBuy$27.00 ➝ $25.00Low
11/11/2022Piper SandlerBoost TargetOverweight ➝ Overweight$22.00 ➝ $24.00Low
10/31/2022GuggenheimInitiated CoverageBuy$15.00Low
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$28.00Low
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$28.00Low
6/10/2022Roth CapitalInitiated CoverageBuyHigh
5/23/2022HC WainwrightInitiated CoverageBuy$27.00Low
5/16/2022Piper SandlerLower TargetOverweight$38.00 ➝ $22.00Low
5/12/2022William BlairInitiated CoverageMarket PerformHigh
3/18/2022SVB LeerinkReiterated RatingBuy$32.00High
11/19/2021SVB LeerinkLower TargetOutperform$33.00 ➝ $32.00Medium
8/15/2021SVB LeerinkReiterated RatingBuyHigh
7/13/2021SVB LeerinkInitiated CoverageOutperform$33.00High
7/13/2021JPMorgan Chase & Co.Initiated CoverageOverweight$40.00High
7/13/2021Bank of AmericaInitiated CoverageBuy$34.00High
7/13/2021Piper SandlerInitiated CoverageOverweight$38.00High
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/30/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 3 very positive mentions
  • 13 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 3 very positive mentions
  • 13 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Century Therapeutics logo
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $3.40
Low: $3.37
High: $3.61

50 Day Range

MA: $4.35
Low: $3.46
High: $5.11

52 Week Range

Now: $3.40
Low: $3.37
High: $14.00

Volume

79,692 shs

Average Volume

213,206 shs

Market Capitalization

$201.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Century Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Century Therapeutics in the last year: Bank of America Co., Canaccord Genuity Group Inc., Chardan Capital, EF Hutton Acquisition Co. I, Guggenheim, HC Wainwright, Piper Sandler, Roth Capital, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for IPSC.

What is the current price target for Century Therapeutics?

9 Wall Street analysts have set twelve-month price targets for Century Therapeutics in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 458.8%. Canaccord Genuity Group Inc. has the highest price target set, predicting IPSC will reach $28.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $14.00 for Century Therapeutics in the next year.
View the latest price targets for IPSC.

What is the current consensus analyst rating for Century Therapeutics?

Century Therapeutics currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IPSC will outperform the market and that investors should add to their positions of Century Therapeutics.
View the latest ratings for IPSC.

What other companies compete with Century Therapeutics?

Other companies that are similar to Century Therapeutics include Jasper Therapeutics, Molecular Partners, Genfit, ARYA Sciences Acquisition Corp IV and Fennec Pharmaceuticals. Learn More about companies similar to Century Therapeutics.

How do I contact Century Therapeutics' investor relations team?

The company's listed phone number is 267-817-5790 and its investor relations email address is [email protected] The official website for Century Therapeutics is www.centurytx.com. Learn More about contacing Century Therapeutics investor relations.